A phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory mantle cell lymphoma.
暂无分享,去创建一个
J. Raemaekers | M. Pfreundschuh | H. Tilly | H. Kluin-Nelemans | F. Reyes | M. Dreyling | N. Milpied | F. Morschhauser | J. Seymour | G. Cartron | A. Grigg | A. Spencer | M. Wolf | A. Pezzutto | M. B. van 't Veer
[1] J. Vose,et al. Phase II study of enzastaurin, a protein kinase C beta inhibitor, in patients with relapsed or refractory diffuse large B-cell lymphoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[2] C. Dumontet,et al. Heterogeneity of protein kinase C β2 expression in lymphoid malignancies , 2007, Histopathology.
[3] R. Herbst,et al. Phase I dose escalation and pharmacokinetic study of enzastaurin, an oral protein kinase C beta inhibitor, in patients with advanced cancer. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] J. Doroshow,et al. Drug development in oncology: classical cytotoxics and molecularly targeted agents. , 2006, British journal of clinical pharmacology.
[5] J. Schellens,et al. Phase I and pharmacokinetic evaluation of enzastaurin combined with gemcitabine and cisplatin in advanced cancer. , 2006, Journal of Clinical Oncology.
[6] R. Camidge,et al. A phase I dose-escalation and pharmacokinetic study of enzastaurin combined with capecitabine in patients with advanced cancer. , 2006, Journal of Clinical Oncology.
[7] H. Sanjo,et al. The Journal of Experimental Medicine CORRESPONDENCE , 2005 .
[8] C. Moskowitz. Mantle cell lymphomas. , 2005, Clinical advances in hematology & oncology : H&O.
[9] W. Chan,et al. Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma , 2005, Modern Pathology.
[10] W. Klapper,et al. Histopathology, cell proliferation indices and clinical outcome in 304 patients with mantle cell lymphoma (MCL): a clinicopathological study from the European MCL Network , 2005, British journal of haematology.
[11] T. Witzig. Current treatment approaches for mantle-cell lymphoma. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[12] R. Campbell,et al. The Protein Kinase Cβ–Selective Inhibitor, Enzastaurin (LY317615.HCl), Suppresses Signaling through the AKT Pathway, Induces Apoptosis, and Suppresses Growth of Human Colon Cancer and Glioblastoma Xenografts , 2005 .
[13] M. Zago,et al. Gene expression profiling of mantle cell lymphoma cells reveals aberrant expression of genes from the PI3K‐AKT, WNT and TGFβ signalling pathways , 2005, British journal of haematology.
[14] E. Hoster,et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the Germa , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[15] S. Bao,et al. The activation of Akt/PKB signaling pathway and cell survival , 2005, Journal of cellular and molecular medicine.
[16] J. Armitage,et al. Clinical relevance of circulating angiogenic factors in patients with non-Hodgkin's lymphoma or Hodgkin's lymphoma. , 2004, Leukemia research.
[17] W. Hiddemann,et al. Mantle cell lymphoma: established therapeutic options and future directions , 2004, Annals of Hematology.
[18] Nerea Martínez,et al. The molecular signature of mantle cell lymphoma reveals multiple signals favoring cell survival. , 2003, Cancer research.
[19] M. Faul,et al. Acyclic N-(azacycloalkyl)bisindolylmaleimides: isozyme selective inhibitors of PKCbeta. , 2003, Bioorganic & medicinal chemistry letters.
[20] L. Staudt,et al. The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma. , 2003, Cancer cell.
[21] M. Teitell,et al. PKC-β controls IκB kinase lipid raft recruitment and activation in response to BCR signaling , 2002, Nature Immunology.
[22] A. Tarakhovsky,et al. Protein Kinase C (cid:2) Controls Nuclear Factor (cid:3) B Activation in B Cells Through Selective Regulation of the I (cid:3) B Kinase (cid:4) , 2002 .
[23] D. Rawlings,et al. Emerging roles for PKC isoforms in immune cell function. , 2002, Molecular Interventions.
[24] J. Gribben,et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[25] J. Leonard,et al. Biology and management of mantle cell lymphoma , 2001, Current opinion in oncology.
[26] G. Mcmahon,et al. VEGF receptor signaling in tumor angiogenesis. , 2000, The oncologist.
[27] A. Goldhirsch,et al. Angiogenic growth factors and endostatin in non‐Hodgkin's lymphoma , 1999, British journal of haematology.
[28] J. Monroe,et al. Antigen receptor-induced signal transduction imbalances associated with the negative selection of immature B cells. , 1999, Journal of immunology.
[29] M. Tiemann,et al. Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[30] B. Nathwani,et al. A clinical evaluation of the International Lymphoma Study Group Classification of non-Hodgkin's lymphoma: a report of the Non-Hodgkin's Lymphoma Classification Project , 1997 .
[31] E. Noordijk,et al. Mantle-cell lymphoma: a population-based clinical study. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[32] F. Cavalli,et al. Patterns of survival in mantle cell lymphoma. , 1995, Annals of oncology : official journal of the European Society for Medical Oncology.
[33] M. Teitell,et al. PKC-beta controls I kappa B kinase lipid raft recruitment and activation in response to BCR signaling. , 2002, Nature immunology.
[34] Todd,et al. Diffuse large B-cell lymphoma outcome prediction by gene-expression profiling and supervised machine learning , 2002, Nature Medicine.
[35] Beverly A. Teicher,et al. Antiangiogenic effects of a protein kinase Cβ-selective small molecule , 2001, Cancer Chemotherapy and Pharmacology.
[36] J. Gastearena,et al. Successful treatment of AA amyloidosis secondary to Hodgkin's disease with 4'-iodo-4'-deoxydoxorubicin. , 1999, Haematologica.
[37] J. Monroe,et al. Biochemistry of antigen receptor signaling in mature and developing B lymphocytes. , 1997, Critical reviews in immunology.
[38] M. Rodriguez,et al. Mantle cell lymphomas. , 1996, Cancer treatment and research.